References

Therapeutic targeting of ALS pathways: refocusing an incomplete picture

10.1002/acn3.51887 · ExternalCitation · doi-reference

Design and statistical innovations in a platform trial for amyotrophic lateral sclerosis

10.1002/ana.26714 · ExternalCitation · doi-reference

Brain-derived neurotrophic factor attenuates cognitive impairment and motor deficits in a mouse model of Parkinson’s disease

10.1002/brb3.2251 · ExternalCitation · doi-reference

Fly for ALS: drosophila modeling on the route to amyotrophic lateral sclerosis modifiers

10.1007/s00018-021-03905-8 · ExternalCitation · doi-reference

Narrative review of diagnosis, management and treatment of dysphagia and sialorrhea in amyotrophic lateral sclerosis

10.1007/s00415-024-12657-x · ExternalCitation · doi-reference

Resting state fMRI analysis of pseudobulbar affect in amyotrophic lateral sclerosis (ALS): motor dysfunction of emotional expression

10.1007/s11682-022-00744-4 · ExternalCitation · doi-reference

Translating the ALS genetic revolution into therapies: a review

10.1007/s11940-024-00781-y · ExternalCitation · doi-reference

Omics-based exploration and functional validation of neurotrophic factors and histamine as therapeutic targets in ALS

10.1016/j.arr.2020.101121 · ExternalCitation · doi-reference

Cell therapy in ALS: an update on preclinical and clinical studies

10.1016/j.brainresbull.2023.01.008 · ExternalCitation · doi-reference

Prognostic factors and epidemiology of amyotrophic lateral sclerosis in Southeastern United States

10.1016/j.mayocpiqo.2024.07.008 · ExternalCitation · doi-reference

Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs

10.1016/j.neuron.2016.04.006 · ExternalCitation · doi-reference

Gene therapy for ALS: a review

10.1016/j.ymthe.2021.04.008 · ExternalCitation · doi-reference

Amyotrophic lateral sclerosis

10.1016/s0140-6736(17)31287-4 · ExternalCitation · doi-reference

Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study

10.1016/s1474-4422(24)00216-3 · ExternalCitation · doi-reference

TDP-43: a key therapeutic target beyond amyotrophic lateral sclerosis

10.1021/acschemneuro.9b00026 · ExternalCitation · doi-reference

Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity

10.1038/mt.2008.60 · ExternalCitation · doi-reference

Decoding ALS: from genes to mechanism

10.1038/nature20413 · ExternalCitation · doi-reference

Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS

10.1038/nn.2660 · ExternalCitation · doi-reference

State of play in amyotrophic lateral sclerosis genetics

10.1038/nn.3584 · ExternalCitation · doi-reference

Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy

10.1038/s10038-022-01055-8 · ExternalCitation · doi-reference

ATAXIN-2 intermediate-length polyglutamine expansions elicit ALS-associated metabolic and immune phenotypes

10.1038/s41467-024-51676-0 · ExternalCitation · doi-reference

C9orf72-mediated ALS and FTD: multiple pathways to disease

10.1038/s41582-018-0047-2 · ExternalCitation · doi-reference

Improving clinical trial outcomes in amyotrophic lateral sclerosis

10.1038/s41582-020-00434-z · ExternalCitation · doi-reference

Prospects for gene replacement therapies in amyotrophic lateral sclerosis

10.1038/s41582-022-00751-5 · ExternalCitation · doi-reference

Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent

10.1038/s41591-018-0140-5 · ExternalCitation · doi-reference

Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis

10.1038/s41591-021-01615-z · ExternalCitation · doi-reference

Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis

10.1056/nejmoa1916945 · ExternalCitation · doi-reference

SOD1 suppression with adeno-associated virus and MicroRNA in familial ALS

10.1056/nejmoa2005056 · ExternalCitation · doi-reference

Trial of antisense oligonucleotide tofersen for SOD1 ALS

10.1056/nejmoa2204705 · ExternalCitation · doi-reference

Amyotrophic lateral sclerosis

10.1056/nejmra1603471 · ExternalCitation · doi-reference

Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis

10.1080/14656566.2017.1319937 · ExternalCitation · doi-reference

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

10.1080/14660820310002601 · ExternalCitation · doi-reference

Simple animal models for amyotrophic lateral sclerosis drug discovery

10.1080/17460441.2016.1196183 · ExternalCitation · doi-reference

Amyotrophic lateral sclerosis estimated prevalence cases from 2022 to 2030, data from the national ALS registry

10.1080/21678421.2024.2447919 · ExternalCitation · doi-reference

Amyotrophic lateral sclerosis: a clinical review

10.1111/ene.14393 · ExternalCitation · doi-reference

Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis

10.1126/scitranslmed.aai7866 · ExternalCitation · doi-reference

Antisense oligonucleotide therapy for neurodegenerative disease

10.1172/jci25424 · ExternalCitation · doi-reference

Emerging mechanisms of molecular pathology in ALS

10.1172/jci71601 · ExternalCitation · doi-reference

Effects of noninvasive ventilation in amyotrophic lateral sclerosis: the complication of bulbar impairment

10.1177/2514183x20914183 · ExternalCitation · doi-reference

TBK1, a prioritized drug repurposing target for amyotrophic lateral sclerosis: evidence from druggable genome Mendelian randomization and pharmacological verification in vitro

10.1186/s12916-024-03314-1 · ExternalCitation · doi-reference

Genetically modified large animal models for investigating neurodegenerative diseases

10.1186/s13578-021-00729-8 · ExternalCitation · doi-reference

Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges

10.1186/s40035-023-00377-7 · ExternalCitation · doi-reference

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis

10.1186/s40035-023-00380-y · ExternalCitation · doi-reference

Pathogenesis of FUS-associated ALS and FTD: insights from rodent models

10.1186/s40478-016-0358-8 · ExternalCitation · doi-reference

Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition

10.1186/s40478-023-01671-1 · ExternalCitation · doi-reference

Pain in amyotrophic lateral sclerosis: a narrative review

10.12701/jyms.2022.00332 · ExternalCitation · doi-reference

The heritability of amyotrophic lateral sclerosis in a clinically ascertained United States research registry

10.1371/journal.pone.0027985 · ExternalCitation · doi-reference

Amyotrophic lateral sclerosis: an update for 2013 clinical features, pathophysiology, management and therapeutic trials

10.14336/ad.2013.0400295 · ExternalCitation · doi-reference

DNA damage, defective DNA repair, and neurodegeneration in amyotrophic lateral sclerosis

10.3389/fnagi.2022.786420 · ExternalCitation · doi-reference

Beta2-adrenergic suppression of neuroinflammation in treatment of parkinsonism, with relevance for neurodegenerative and neoplastic disorders

10.3390/biomedicines12081720 · ExternalCitation · doi-reference

Gene therapy in amyotrophic lateral sclerosis

10.3390/cells11132066 · ExternalCitation · doi-reference

Gene therapy for ALS-A perspective

10.3390/ijms20184388 · ExternalCitation · doi-reference

Nearly 30 years of animal models to study amyotrophic lateral sclerosis: a historical overview and future perspectives

10.3390/ijms222212236 · ExternalCitation · doi-reference

Gene therapy in ALS and SMA: advances, challenges and perspectives

10.3390/ijms24021130 · ExternalCitation · doi-reference

Advances and challenges in gene therapy for neurodegenerative diseases: a systematic review

10.3390/ijms252312485 · ExternalCitation · doi-reference

The potential of the nose-to-brain delivery of PACAP for the treatment of neuronal disease

10.3390/pharmaceutics15082032 · ExternalCitation · doi-reference